Jeffrey Farrow compensation by year
Tarsus Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $541,667 |
| Bonus | $0 |
| Stock awards | $893,961 |
| Option awards | $895,011 |
| Non-equity incentive | $264,900 |
| Pension and deferred compensation | $0 |
| All other | $82,078 |
| Total | $2,677,617 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 28, 2026, accession 0001819790-26-000028, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 55,763 | $4,565,874 | — |
| RSU | 24,060 | $1,970,033 | — |
| RSU | 20,089 | $1,644,887 | — |
| RSU | 7,508 | $614,755 | — |
| Option | 30,628 | — | $44.54 |
| Option | 54,466 | — | $14.62 |
| Option | 26,719 | — | $35.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Tarsus Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-16 | Sale | — | 14,396 | $60.95 | 56,801 |
| 2026-06-15 | Exercise or conversion | — | 27,881 | — | 71,197 |
| 2026-06-15 | Exercise or conversion derivative | — | 27,881 | $0.00 | 27,882 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Tarsus Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $545,000 | $0 | $40,018 | $585,018 |
| Change in control and involuntary termination | $1,035,500 | $19,145,177 | $40,018 | $20,220,695 |
Per the Potential Payments Upon Termination or Change in Control table in Tarsus Pharmaceuticals, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Tarsus Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bobak Azamian | President, Chief Executive Officer and Board Chairman | $6,617,979 |
| Aziz Mottiwala | Chief Commercial Officer | $2,789,529 |
| Jeffrey Farrow · this page | Chief Financial Officer and Chief Strategy Officer | $2,677,617 |
| Seshadri Neervannan | Chief Operating Officer | $2,628,172 |
| Bryan Wahl | General Counsel and Corporate Secretary | $2,560,205 |
The full Tarsus Pharmaceuticals compensation record
free company briefThis page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Tarsus Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat